FC
FLNA

Farringdon Capital’s Filana Therapeutics FLNA Stock Holding History

Farringdon Capital’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,346
Closed -$18.5K – 577
2025
Q1 		$18.5K Buy
+12,346
New +$31.2K 0.01% 324

Other funds holding FLNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Farringdon Capital's FLNA Position: Q2 2025 in Review

Farringdon Capital sold out of Filana Therapeutics (FLNA) in Q2 2025, closing a stake of 12,346 shares — an estimated $18.5K sold.

Farringdon Capital first reported a position in FLNA in Q1 2025 and held it in 1 quarter. The position peaked at $18.5K in Q1 2025. 97 funds tracked by Wall St. Rank hold FLNA as of Q2 2025.

  • Farringdon Capital reported no remaining Filana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Farringdon Capital sold 12,346 Filana Therapeutics shares in Q2 2025, an estimated $18.5K.
  • Farringdon Capital first reported a position in Filana Therapeutics in Q1 2025 and held it in 1 quarter.
  • Farringdon Capital's Filana Therapeutics position peaked at $18.5K in Q1 2025.
  • 97 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2025.

Based on Farringdon Capital's 13F filing for Q2 2025, filed 14 Aug 2025.